KM 23

Drug Profile

KM 23

Alternative Names: KM 023

Latest Information Update: 20 Jan 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Kainos Medicines
  • Developer Kainos Medicines; Unknown
  • Class
  • Mechanism of Action Non-nucleoside reverse transcriptase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes - HIV infections

Highest Development Phases

  • Phase II HIV infections

Most Recent Events

  • 20 Jan 2017 Phase-II clinical trials in HIV infections (PO) (Kainos Medicine website, January 2017)
  • 07 Mar 2016 Phase I development is ongoing in South Korea
  • 07 Mar 2016 KM 23 is available for licensing as of 07 Mar 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top